Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT05113888 Not yet recruiting - Clinical trials for Irritable Bowel Syndrome

Exploratory Study on Dosage of Qizhi Weitong Granules in the Treatment of Irritable Bowel Syndrome (IBS)

Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study are as follows: 1) To evaluate the efficacy and safety of Qizhi Weitong granules in the treatment of diarrhea-type irritable bowel syndrome (IBS-D);2) To explore the dosage of Qizhi Weitong Granulesin treatment of IBS-D.

NCT ID: NCT05113121 Completed - Clinical trials for Pseudoexfoliation Syndrome

Correlation Between Pupil Size and Ocular Signs of Pseudoexfoliation Syndrome

Start date: August 25, 2021
Phase:
Study type: Observational [Patient Registry]

To study possible correlation between the size of the pupil in both room light and after dilation between both eyes in bilateral pseudoexfoliation with Intraocular pressure, lens clarity and stability, Optic disc , Visual changes and glaucoma changes by optical coherence tomography

NCT ID: NCT05113082 Completed - Clinical trials for Short Bowel Syndrome (SBS)

Retrospective Study on Participants With Short Bowel Syndrome and Chronic Intestinal Failure That Underwent Transplantation in Brazil

Start date: May 21, 2022
Phase:
Study type: Observational

The main aim of this study is to capture management and treatment outcome data in participants with short bowel syndrome and chronic intestinal failure (SBS-IF) that underwent intestinal transplantation in Brazil. This study is about collecting data available in the participant's medical record and will also describe the demographic and clinical characteristics of these participants. No medication will be provided to participants in this study. Clinical data will be collected from a period up to 10 years before the day of the intestinal transplantation. No clinic visits will be required as part of participation in this study.

NCT ID: NCT05113030 Completed - Clinical trials for Polycystic Ovary Syndrome

Impact of PCOS on Periodontal Status of Adolescent and Adult Age Group Women

Start date: November 1, 2021
Phase:
Study type: Observational

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women, primarily affecting the reproductive system, with substantial collateral negative health effects on metabolic, psychological, and cardiovascular functions. Patients with this syndrome are at higher risk of developing insulin resistance (IR), obesity, dyslipidemia, cardiovascular disease (CVD), and endometrial carcinoma.IR and hyperinsulinemia are responsible for the low-grade chronic systemic inflammation. Periodontitis, an immuno-inflammatory disease, is a result of interaction between bacterial attack and host inflammatory response, causing inflammation of supporting tissues of the teeth leading to tissue destruction and tooth loss. Chronic low-grade inflammation is emerging as a plausible etiologic mechanism linking periodontal disease and many systemic diseases. Previous cross-sectional studies described a possible relationship between PCOS and periodontitis and the impact of PCOS on gingival inflammation and vice-versa in terms of increased inflammatory markers (hsCRP, IL-6, IL-17 and TNF-α). In PCOS females, there is an alteration of various hormone levels in the body. Female sex steroid hormones play a key role in periodontal disease progression and periodontal and implant wound healing. Human gingiva has the capacity to metabolize hormones such as estrogen and progesterone. Moreover, gingival tissue exhibits receptors for such hormones and it is considered as a target organ for their direct action. These hormones might act on gingival cells by changing the effectiveness of the epithelial barrier to bacterial injury or by affecting the collagen maintenance and repair. To avoid periodontal implications as these hormonal changes can worsen the vulnerability to plaque-induced periodontal disease. So, present study is going to conduct in females with PCOS and periodontitis at different age groups like adolescent and adult age groups. AIM - Assessment of impact of polycystic ovary syndrome on periodontal status of women of adolescent and adult age groups.

NCT ID: NCT05113004 Recruiting - Clinical trials for Primary Sjögren's Syndrome (pSS)

New Clinical End-points in Patients With Primary Sjögren's Syndrome

NECESSITY
Start date: January 20, 2022
Phase: Phase 2
Study type: Interventional

There are no approved treatments for pSS and the clinical endpoints currently used in clinical trials are inadequate to capture all aspects of the disease that should be evaluated in clinical trials. The newly developed composite endpoint: Sjögren's Tool for Assessing Response to treatment (STAR) will allow a more specific and meaningful assessment of treatment efficacy in pSS. Because of the heterogeneity of the disease and of the central role of the interplay between B- and T-cells in the pathogenesis, it is worth to evaluate combination of conventional synthetic immunomodulatory drugs targeting both B- and T-cells.

NCT ID: NCT05112692 Not yet recruiting - Clinical trials for PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries

Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles

Start date: November 2021
Phase: N/A
Study type: Interventional

The purpose of this trial is to compare the efficacy and safety of the PPOS protocol to the GnRH antagonist protocol in patients with PCOS who are undergoing IVF/ICSI cycles.

NCT ID: NCT05108103 Completed - Clinical trials for Complex Regional Pain Syndromes

Determination of Longus Colli Muscle Thickness by Ultrasonography

Start date: March 1, 2021
Phase:
Study type: Observational

This study aims to assess the longus colli muscle thickness by ultrasonography in order to guide stellate ganglion blocks

NCT ID: NCT05107635 Recruiting - Clinical trials for Postural Tachycardia Syndrome

Inappropriate Sinus Tachycardia Registry

Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

The primary objective of this registry is to capture the real-world data on the outcome of AtriCure Isolator® Synergy™ Surgical Ablation system (or future iterations) when used to ablate cardiac tissue in patients with Inappropriate Sinus Tachycardia (IST) or Postural Tachycardia Syndrome (POTS) using sinus node sparing hybrid ablation procedures. This is an observational, retrospective and prospective, multicenter, open-label patient registry.

NCT ID: NCT05105685 Completed - Clinical trials for Growth Hormone Treatment

Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS

Start date: June 14, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

In summary, this piot study with 6 participants shown that recombinant human growth hormone (rhGH) has a positive effect on the treatment with PMS. In addition, This study indicated that rhGH can improve PMS symptoms via increase the level of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3). RhGH may be low cost, more accessible, alternative treatment for PMS.

NCT ID: NCT05105321 Not yet recruiting - Metabolic Syndrome Clinical Trials

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

CDPP
Start date: December 2021
Phase: Phase 4
Study type: Interventional

The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).